Results 11 to 20 of about 123,662 (255)

Uremic pruritus: pathophysiology, clinical presentation, and treatments

open access: yesKidney Research and Clinical Practice, 2022
Uremic pruritus is one of the most common and bothersome symptoms in patients with end-stage renal disease. Most patients with uremic pruritus experience a prolonged and relapsing course and significant impairments of quality of life. The pathophysiology
Mei-Ju Ko, Yu-Sen Peng, Hon-Yen Wu
semanticscholar   +1 more source

Uremic Pruritus: From Diagnosis to Treatment

open access: yesDiagnostics, 2022
Uremic pruritus, or chronic kidney disease-associated pruritus, is common, bothersome, and sometimes debilitating in patients with chronic kidney disease or end-stage renal disease.
An-Yu Cheng, L. Wong
semanticscholar   +1 more source

Scratching increases epidermal neuronal branching and alters psychophysical testing responses in atopic dermatitis and brachioradial pruritus

open access: yesFrontiers in Molecular Neuroscience, 2023
BackgroundChronic scratching imposes a major stress on the skin and can lead to itch intensity worsening, and consequently, patients may enter an itch–scratch cycle.
Lina Renkhold   +9 more
doaj   +1 more source

Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus.

open access: yesNew England Journal of Medicine, 2020
BACKGROUND Nemolizumab is a subcutaneously administered humanized monoclonal antibody against interleukin-31 receptor A, which is involved in pruritus and inflammation in atopic dermatitis.
K. Kabashima   +3 more
semanticscholar   +1 more source

Chronic Kidney Disease-Associated Pruritus

open access: yesToxins, 2021
Pruritus is a distressing condition associated with end-stage renal disease (ESRD), advanced chronic kidney disease (CKD), as well as maintenance dialysis and adversely affects the quality of life (QOL) of these patients.
P. Agarwal   +5 more
semanticscholar   +1 more source

Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate‐to‐severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long‐term studies

open access: yesBritish Journal of Dermatology, 2021
Interleukin (IL)‐31 affects the inflammatory response, is involved in epidermal barrier disruption in atopic dermatitis (AD) and plays a key role in pruritus.
K. Kabashima   +3 more
semanticscholar   +1 more source

S2k guideline: Diagnosis and treatment of chronic pruritus

open access: yesJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2022
Pruritus is a cross‐disciplinary leading symptom of numerous diseases and represents an interdisciplinary diagnostic and therapeutic challenge. In contrast to acute pruritus, chronic pruritus (CP) is a symptom of various diseases that is usually ...
S. Ständer   +16 more
semanticscholar   +1 more source

IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH

open access: yesHepatology, 2022
Background and Aims: Pruritus is associated with multiple liver diseases, particularly those with cholestasis, but the mechanism remains incompletely understood.
Jun Xu   +20 more
semanticscholar   +1 more source

Pruritus in Keloid Scars: Mechanisms and Treatments

open access: yesActa Dermato-Venereologica, 2021
Keloids are scars that extend beyond the margins of an insulting cutaneous injury. Keloids are often thought to be primarily a cosmetic issue, as they are typically quite raised and pigmented. However, these scars also present with functional symptoms of
A. Hawash   +3 more
semanticscholar   +1 more source

Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis

open access: yesLiver international (Print), 2021
Primary biliary cholangitis (PBC) can result in life‐altering cholestatic pruritus and fatigue, but treatment options are limited. Seladelpar, a peroxisome proliferator‐activated receptor‐delta (PPARδ) agonist, has demonstrated potent anti‐cholestatic ...
A. Kremer   +8 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy